BioStock interviews our CEO on the path to Phase 2
Date: 2025-05-04
As Alzinova advances toward Phase 2, CEO Tord Labuda shares his perspective on what sets the company apart in the global Alzheimer’s landscape.
The article also covers the ongoing rights issue and the preparations for the upcoming Phase 2 clinical trial.
Read the interview (in Swedish)